At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ABVX Abivax S.A.
Post-Mkt 08-07 16:02:18 EDT
130.93
+0.93
+0.72%
盘后130.93
+0.000.00%
16:00 EDT
High133.52Low130.01Vol898.19K
Open132.05D1 Closing130.00Amplitude2.70%
Mkt Cap11.40BTradable Cap9.68BTotal Shares87.05M
T/O117.95MT/O Rate1.22%Tradable Shares73.91M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Abivax Announces Positive Pre-Nda Interaction with the FDA for Obefazimod
THOMSON REUTERS  ·  07-31
Abivax Announces Positive Pre-Nda Interaction with the FDA for Obefazimod
Abivax Sa: Remains on Track to Submit First Nda for Obefazimod for Treatment of Moderately to Severely Active Ulcerative Colitis by End of 2026
THOMSON REUTERS  ·  07-31
Abivax Sa: Remains on Track to Submit First Nda for Obefazimod for Treatment of Moderately to Severely Active Ulcerative Colitis by End of 2026
Movement Alert｜Abivax S.A. Rises 5.18% in Regular Trading, Morgan Stanley Raises Target Price to $180
Market Focus  ·  07-30
Movement Alert｜Abivax S.A. Rises 5.18% in Regular Trading, Morgan Stanley Raises Target Price to $180
Abivax's Potential Colitis Drug Showing Positive Results That Bolster Stock Prospects, Morgan Stanley Says
MT Newswires Live  ·  07-24
Abivax's Potential Colitis Drug Showing Positive Results That Bolster Stock Prospects, Morgan Stanley Says
Morgan Stanley Adjusts Price Target on Abivax to $180 From $132, Maintains Overweight Rating
MT Newswires Live  ·  07-24
Morgan Stanley Adjusts Price Target on Abivax to $180 From $132, Maintains Overweight Rating
Abivax Names New Global Heads of Marketing, Sales and Market Access in Commercial Leadership Shake-up
Reuters  ·  07-24
Abivax Names New Global Heads of Marketing, Sales and Market Access in Commercial Leadership Shake-up
Abivax re-engages Centerview amid renewed takeover interest, La Lettre says
TIPRANKS  ·  07-18
Abivax re-engages Centerview amid renewed takeover interest, La Lettre says
Valerio Therapeutics, Abivax Enter R&D Collaboration for Inflammatory Disease Therapies
MT Newswires Live  ·  07-16
Valerio Therapeutics, Abivax Enter R&D Collaboration for Inflammatory Disease Therapies
Abivax price target raised to $175 from $165 at Piper Sandler
TIPRANKS  ·  07-09
Abivax price target raised to $175 from $165 at Piper Sandler
Abivax Closes $920 Million ADS Offering
MT Newswires Live  ·  07-07
Abivax Closes $920 Million ADS Offering
Abivax Rebounds, but Obefazimod Unlikely to Replace JAK Inhibitors, Wedbush Says
MT Newswires Live  ·  07-06
Abivax Rebounds, but Obefazimod Unlikely to Replace JAK Inhibitors, Wedbush Says
Abivax Sa : Wedbush Raises Target Price to $140 from $110
THOMSON REUTERS  ·  07-06
Abivax Sa : Wedbush Raises Target Price to $140 from $110
Wedbush Raises Price Target on Abivax to $140 From $110, Keeps Neutral Rating
MT Newswires Live  ·  07-06
Wedbush Raises Price Target on Abivax to $140 From $110, Keeps Neutral Rating
Movement Alert｜Abivax S.A. Rises 6.46% in Pre-Market Trading, $920 Million ADS Offering Officially Closes Boosting Bullish Sentiment
Market Focus  ·  07-06
Movement Alert｜Abivax S.A. Rises 6.46% in Pre-Market Trading, $920 Million ADS Offering Officially Closes Boosting Bullish Sentiment
Movement Alert｜Abivax S.A. Rises 5.74% Overnight, $920 Million ADS Offering Officially Closes as Underwriters Fully Exercise Over-Allotment Option
Market Focus  ·  07-06
Movement Alert｜Abivax S.A. Rises 5.74% Overnight, $920 Million ADS Offering Officially Closes as Underwriters Fully Exercise Over-Allotment Option
Movement Alert｜Abivax S.A. Rises 5.39% in Regular Trading, Underwriters Fully Exercise Overallotment Option Lifting Total Proceeds to $920 Million
Market Focus  ·  07-02
Movement Alert｜Abivax S.A. Rises 5.39% in Regular Trading, Underwriters Fully Exercise Overallotment Option Lifting Total Proceeds to $920 Million
Abivax Sa : Truist Securities Raises Target Price to $155 from $135
THOMSON REUTERS  ·  07-02
Abivax Sa : Truist Securities Raises Target Price to $155 from $135
Abivax price target raised to $155 from $135 at Truist
TIPRANKS  ·  07-02
Abivax price target raised to $155 from $135 at Truist
Abivax Says Underwriters Fully Exercise Option in ADS Offering
MT Newswires Live  ·  07-02
Abivax Says Underwriters Fully Exercise Option in ADS Offering
Analysts Offer Insights on Healthcare Companies: SCYNEXIS (SCYX) and Abivax SA Sponsored ADR (ABVX)
TIPRANKS  ·  07-02
Analysts Offer Insights on Healthcare Companies: SCYNEXIS (SCYX) and Abivax SA Sponsored ADR (ABVX)

Introduction

Company Name.
Abivax S.A.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.
Issue price:
--